Patient sex and gut microbiome play a role in modulating response to immunotherapy
Research is ongoing to investigate influencing factors of immune checkpoint inhibition, encouraging a more holistic understanding of individual characteristics to improve clinical outcomes
Quality cancer care starts with training oncologists at the highest standards
Despite the encouraging findings of a new global survey demonstrating a high rate of uptake of the ESMO/ASCO Global Curriculum in Medical Oncology, resource limitations in lower-income regions as well as country-specific political circumstances may be hindering its implementation locally.
What do non-oncologists know about cancer care?
A survey reveals that physicians outside the field of oncology are insufficiently updated on the latest advances in cancer care, thus increasing the risk of providing misleading information and inadequate support to patients.
Optimising clinical trials for greater inclusiveness
Oncologists are aiming to capitalise on lessons learned from the COVID-19 pandemic and design more inclusive clinical trials, optimise trial endpoints and make better use of real-world evidence.
Anti-cancer medicines are typically approved in the USA eight months before Europe
Discrepancies in anti-cancer drug approvals around the globe are even bigger in low- and middle-income countries, raising some questions about how they impact on patients’ access to quality cancer care.
Bringing a child into a family’s battle with cancer
Available data now allows evidence-based treatment of cancer diagnosed during pregnancy and new therapies are improving many young patients’ survival prospects, but couples’ preferences and values must continue to guide medical teams even when hope is scarce
Milestone in hereditary breast cancer: PARP inhibition benefits women with early-stage disease
Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women
Hereditary cancers: diagnosed patients are only the tip of the iceberg
Although knowledge on pathogenic germline variants has improved over the years, researchers are hunting for new genetic causes of cancer to better identify families at higher risk to develop the disease